{"filing":{"accession_number":"0001193125-26-233375","cik":"0002114044","ticker":"COAG","company_name":"Hemab Therapeutics Holdings, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"d102408d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/d102408d8k.htm"},"events":[{"id":9373,"run_id":8220,"accession_number":"0001193125-26-233375","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"The filing discloses a press release announcing financial results for the quarter ended March 31, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard earnings release disclosure with the press release furnished as Exhibit 99.1, which is material to investors assessing the company's operational and financial performance.","company_name":"Hemab Therapeutics Holdings, Inc.","ticker":"COAG","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":985,"accession_number":"0001193125-26-233375","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses a press release announcing financial results for the quarter ended March 31, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard earnings release disclosure with the press release furnished as Exhibit 99.1, which is material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:35:38.411626+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":985,"accession_number":"0001193125-26-233375","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses a press release announcing financial results for the quarter ended March 31, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard earnings release disclosure with the press release furnished as Exhibit 99.1, which is material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:35:38.411626+00:00","company_name":"Hemab Therapeutics Holdings, Inc.","ticker":"COAG","filing_date":"2026-05-21"}]}